ABSI
$9.18
$-0.28 (-2.96%)-2.96%
After HoursLoading chart...
IndexN/A
Market Cap1.56B
Enterprise Value0.46B
Income$-0.03B
Sales$0.00B
EmployeesN/A
P/E-10.67
P/S170.48
P/B2.52
P/C-5.08
EV/EBITDA-4.48
EV/SalesN/A
EPS (ttm)-0.86
EarningsN/A
Gross Margin-319.36%
Oper. Margin-4454.21%
Profit Margin-4113.68%
Volume2.23M
Shs Outstand0.17B
Change-2.96%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $4.53M | $5.72M | $5.75M | $4.78M | $4.78M | $2.06M |
| Cost of Revenue | $62.46M | $47.57M | $58.91M | $44.59M | $11.45M | $0.00 |
| Gross Profit | $-57.92M | $-41.85M | $-53.16M | $-39.80M | $-6.67M | $2.06M |
| Gross Margin | -1277.57% | -731.88% | -925.02% | -832.37% | -139.50% | 100.00% |
| Operating Expenses | $50.96M | $73.67M | $53.59M | $35.43M | $6.63M | $8.32M |
| Operating Income | $-108.89M | $-115.52M | $-106.75M | $-75.24M | $-13.30M | $-6.26M |
| Operating Margin | -2401.59% | -2020.20% | -1857.49% | -1573.36% | -278.26% | -304.13% |
| Net Income | $-103.11M | $-110.57M | $-104.90M | $-100.96M | $-14.35M | $-6.58M |
| Net Margin | -2274.06% | -1933.65% | -1825.37% | -2111.25% | -300.27% | -319.61% |
| EPS (Basic) | $-0.94 | $-1.20 | $-1.15 | $-1.11 | $-0.54 | $-0.07 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $213.61M | $217.30M | $321.01M | $426.19M | $88.57M | $19.47M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $34.48M | $41.12M | $46.59M | $60.09M | $21.56M | $60.63M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $179.13M | $176.18M | $274.41M | $366.11M | $67.00M | $-41.16M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $179.13M | $176.18M | $274.41M | $366.11M | $67.00M | $-41.16M |
| Total Liabilities & Stockholders Equity | $213.61M | $217.30M | $321.01M | $426.19M | $88.57M | $19.47M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-103.11M | $-110.57M | $-104.90M | $-100.96M | $-14.35M | $-6.58M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-72.40M | $-64.64M | $-81.34M | $-60.60M | $-10.97M | $-6.03M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItBenzinga AMD Reveals A $6.5 Million Marvell Bet That's Already SoaringBenzinga Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical OfficerGlobeNewswire Inc. Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025Benzinga Absci to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. Absci Stock Offers High-Risk AI Biotech Exposure With 110% Upside ForecastInvesting.com Computer-Aided Drug Design (CADD) Market Competitive Landscape Report – Towards HealthcareGlobeNewswire Inc.
Show 12 more stories
Absci Boosts AI-Powered Drug Discovery With Oracle And AMD CollaborationBenzinga Absci to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsightGlobeNewswire Inc. Absci Announces Pricing of Public Offering of Common StockBenzinga Absci Announces Pricing of Public Offering of Common StockGlobeNewswire Inc. Absci Announces Proposed Public Offering of Common StockGlobeNewswire Inc. Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. Absci to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswire Inc. Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug DiscoveryGlobeNewswire Inc. AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient CareBenzinga 4 Biotech Stocks With AI, Machine Learning ProwessInvesting.com Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtThe Motley Fool
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Discover more
You may be interested in